Trials / Completed
CompletedNCT00568321
RN624 For Pain Of Post-Herpetic Neuralgia
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RN624 | 50 mcg/kg |
| DRUG | RN624 | 200 mcg/kg |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2007-12-19
- Primary completion
- 2008-12-20
- Completion
- 2009-01-07
- First posted
- 2007-12-06
- Last updated
- 2021-05-28
- Results posted
- 2021-05-28
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00568321. Inclusion in this directory is not an endorsement.